Navigation Links
Merrimack Pharmaceuticals Initiates Enrollment in a Phase 1 Study of MM-121, an ErbB3 Antagonist
Date:8/11/2008

CAMBRIDGE, Mass., Aug. 11 /PRNewswire/ -- Merrimack Pharmaceuticals, Inc. today announced that the first patient has received an initial dose in a Phase 1 clinical study of the Company's first oncology product, MM-121, a fully human monoclonal antibody and a first-in-class therapeutic designed to block signaling of the ErbB3 receptor.

ErbB3 is a receptor in the ErbB family, a pathway that plays a critical role in cancer signaling. With the initiation of the Phase 1 trial, MM-121 becomes the first systems biology product as well as the first selective ErbB3 antagonist to enter human clinical development.

"We used a combination of high-throughput biology and computer simulation to discern the importance of targeting ErbB3 signaling in tumor cells," said Dr. Ulrik B. Nielsen, Senior Vice President of Research. "We believe this is the first systems-designed therapeutic in clinical development. Until now, computer simulation has not been widely applied toward understanding optimal therapeutic strategies for treating cancers driven by complex signaling pathways."

Preclinical data demonstrating the impact of MM-121 in multiple cancer models were presented at the annual meeting of the American Association for Cancer Research in April. The Phase 1 dose escalation study will evaluate the safety and pharmacokinetics (PK) of MM-121. Enrollment is underway at Fox Chase Cancer Center and two additional leading oncology sites are expected to participate in the trial later this year.

"ErbB3 is now recognized as a potentially important target in many types of cancer including lung, breast, colorectal, ovarian and others," said Dr. William J. Slichenmyer, Senior Vice President and Chief Medical Officer at Merrimack. "Preclinical studies of MM-121 have demonstrated antitumor activity in a wide range of tumor types and a very favorable safety profile. We are optimistic that these findings may translate into clinical benefit for patients who participat
'/>"/>

SOURCE Merrimack Pharmaceuticals, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3

Related biology technology :

1. Merrimack Pharmaceuticals Announces the Addition of Robert Gay to its Board of Directors
2. Merrimack Pharmaceuticals Raises $60 Million in Private Financing
3. Vion Pharmaceuticals Pays Interest on 7.75% Convertible Senior Notes
4. China Biopharmaceuticals Holdings Announces Second Quarter 2007 Financial Results
5. Vion Pharmaceuticals Completes Accrual of 85 Patients to its Pivotal Phase II Trial of Cloretazine(R) (VNP40101M) in Elderly AML
6. XTL Biopharmaceuticals Announces Financial Results for the Six Months Ended June 30, 2007
7. Cadence Pharmaceuticals Reports Second Quarter 2007 Financial Results
8. Nabi Biopharmaceuticals to Present at Upcoming Industry Conferences
9. Anadys Pharmaceuticals Appoints Steve Worland, Ph.D. as President and Chief Executive Officer
10. Poniard Pharmaceuticals Announces Participation in Upcoming Conferences
11. NovaQuest Advances Virtual Development Model With Strategic Investment in TOPIGEN Pharmaceuticals
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/24/2015)... 2015 DryLet, LLC a biotechnology ... such as animal waste reduction, bioremediation, wastewater treatment, ... wastewater treatment plants and restaurant kitchen settings, announced ... National Restaurant Association’s NRA Show 2015, in Chicago, ... the company will be available to share information ...
(Date:4/24/2015)... April 24, 2015 /CNW Telbec/ - Mirego, leader in mobile ... making of three mobile app extensions for the all new ... its clients, Familiprix, OMSignal and MediaMiser, these extensions will reinvent ... functions designed specifically for wrist use.  Available ... is a highly customizable tactile smartwatch that makes for an ...
(Date:4/24/2015)... Seoul Semiconductor announced the expansion of ... the lighting market. In recent months, there ... in emerging markets such as Russia, South America, ... applications such as streetlight and area lighting, tunnel ... launched in 2005 the Acrich technology from Seoul ...
(Date:4/23/2015)... Dora, Florida (PRWEB) April 23, 2015 ... that it intends to conduct a groundbreaking pilot ... begin to be reversed in as little as ... the science of metabolic and nutritional medicine—will aggressively ... that cripple and destroy our aging brain. These ...
Breaking Biology Technology:DryLet to Showcase Bio-React at the National Restaurant Association’s NRA Show 2015 May 16-19, 2015 in Chicago, Illinois 2Familiprix, OMSignal and MediaMiser apps available today for Apple Watch 2Acrich Technology from Seoul Semiconductor Adopted in Installations Worldwide 2New Study Looks to Reverse Alzheimer’s Disease 2New Study Looks to Reverse Alzheimer’s Disease 3
... Hu of China - Source: Getty Images The Olympics ... four years. They're held every year. Though this is still ... as the pervasive growth of the industry becomes part of ... every four years and last two weeks, the biotech Olympics ...
... MADISON, Wis. - Ownership and accountability is the way ... 448-bed community hospital in Madison that provides medical care ... living facility, laboratories and a home health care service. ... Methodist Hospital in 1987, Meriter includes more than 430 ...
... trend three years ago many companies cut their information ... the price of computers dropped, allowing businesses to inexpensively ... grew. Many IT staffers are wary of returning to ... looked to begin working as an outside IT source, ...
Cached Biology Technology:The Olympics: A Biotech Perspective 2The Olympics: A Biotech Perspective 3Meriter IT team builds project performance through internal relationships 2Meriter IT team builds project performance through internal relationships 3Meriter IT team builds project performance through internal relationships 4Expetec expands IT staff services in Wisconsin 2Expetec expands IT staff services in Wisconsin 3
(Date:4/14/2015)... 2015  HYPR Corp. today announced it has ... Alliance tm , an industry consortium transforming online ... share technology and collaborate to deliver open specifications ... secure and private, and easier to use. ... protects sensitive user information and eliminates the dependency ...
(Date:4/13/2015)... According to a recently ... & Opportunities, 2020", the global biometrics market is ... till 2020. The biometrics market is garnering attention ... review of biometric management systems. The constant development ... greater efficiency, are resulting in increasing installation of ...
(Date:4/10/2015)... -- Research and Markets ( http://www.researchandmarkets.com/research/cjk4gb/security ) ... Profiles - NEC" report to their offering. ... continue to supply a range of IT security management ... focus on the development of a Big Data and ... the Asia-Pacific region is a ...
Breaking Biology News(10 mins):HYPR Corp. Joins the FIDO Alliance 2HYPR Corp. Joins the FIDO Alliance 3Global Biometrics Market to Cross US$ 21 Billion by 2020: TechSci Research 2NEC Security Competitive Profile 2015 2
... screening the genome of hundreds of thousands of individuals ... more than 100 regions in the genome to the ... Molecular Biology Laboratory (EMBL) and the University of Heidelberg, ... taking these results one step further by pinpointing the ...
... 2013) "Green" chemistry developed at Rice University is at ... waste into fatty acids, and then into fuel. The ... recently announced $25 million United States Department of Agriculture project ... products from switchgrass and forestry residues and from a new ...
... have been a source of great controversyparticularly in Europebut ... scientific evidence about the health and ecological impacts of ... field site dedicated for use in GM crop studies ... interested in pursuing crop biotechnology, according to an article ...
Cached Biology News:Zeroing in on heart disease 2Modified bacteria turn waste into fat for fuel 2Modified bacteria turn waste into fat for fuel 3Fighting GM crop vandalism with a government-protected research site 2
Rabbit polyclonal to GABA A Receptor gamma 2 ( Abpromise for all tested applications). entrezGeneID: 2566 SwissProtID: P18507...
Rabbit polyclonal to VPAC2 ( Abpromise for all tested applications). entrezGeneID: 7434 SwissProtID: P41587...
Anti-GOSR2 Monoclonal AntibodyOther Sub-Family: not assigned-Other Applications: Immunocytochemistry, Immunoprecipitation, Western Blot...
Mouse monoclonal [4A2.2] to SLC6A4 ( Abpromise for all tested applications). entrezGeneID: 6532 SwissProtID: P31645...
Biology Products: